Evommune, a Palo Alto, CA-based clinical-stage biotechnology company, raised additional $7.5M in Series B funding.
The additional funding, which brought the total amount raised in the round to $57.5M, saw participation from Verition Fund Management.
The company intends to use funds to expand operations and its business reach.
Founded in 2020 and led by Luis Peña, President and Chief Executive Officer, Evommune is a private R&D company creating science to treat inflammatory diseases. It is evolving immunology through its human tissue-based approach to discovering, developing, and delivering therapies that address symptoms and halt progressive disease.
FinSMEs
28/06/2023